Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q2 FY22 results · Jul–Sep 2021
Metropolis Healthcare reported revenue from operations of ₹302.62 crore (up 4.9% from Q2 FY21) and net profit of ₹58.40 crore (down 3.5% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 302.62 | 288.35 | +4.9% | 326.76 | −7.4% |
| Other income | 5.57 | 3.08 | +80.7% | 3.76 | +48.1% |
| Total income | 308.19 | 291.44 | +5.7% | 330.53 | −6.8% |
| Profit before tax | 77.71 | 81.39 | −4.5% | 103.08 | −24.6% |
| Net profit for the period | 58.40 | 60.52 | −3.5% | 74.92 | −22.1% |
| Attributable to shareholders of the company | 58.27 | — | — | 74.89 | −22.2% |
| EPS, basic (₹) | 11.39 | 11.88 | −4.1% | 14.65 | −22.3% |
| Net margin (%) | 19.3 | 21.0 | 22.9 |
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 241.96 | 242.55 | −0.2% | 264.10 | −8.4% |
| Other income | 3.30 | 1.83 | +80.8% | 3.28 | +0.7% |
| Total income | 245.26 | 244.37 | +0.4% | 267.38 | −8.3% |
| Profit before tax | 59.46 | 70.09 | −15.2% | 81.73 | −27.2% |
| Net profit for the period | 44.47 | 52.36 | −15.1% | 59.52 | −25.3% |
| EPS, basic (₹) | 8.70 | 11.52 | −24.5% | 11.64 | −25.3% |
| Net margin (%) | 18.4 | 21.6 | 22.5 |
Consolidated
- Filed with BSE
- 11 Nov 2021, 15:26 IST
- Board meeting
- 10 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2021, 15:26 IST
- Board meeting
- 10 Nov 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE